The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Danese S.

Colombel J.-F.

Reinisch W.

Rutgeerts P.J.

Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience

Authors:

Danese S., Colombel J.-F., Reinisch W., Rutgeerts P.J.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2012;(2): 22‑34

Read: 5920 times

Download PDF (RU)
Contact the author
Table of contents

REVIEW ARTICLE: INFLIXIMAB FOR CROHN'S DISEASE TREATMENT - SHIFTING THERAPEUTIC STRATEGIES AFTER 10 YEARS OF CLINICAL EXPERIENCE.
REVIEW ARTICLE: INFLIXIMAB FOR CROHN'S DISEASE TREATMENT - SHIFTING THERAPEUTIC STRATEGIES AFTER 10 YEARS OF CLINICAL EXPERIENCE.

To cite this article:

Danese S, Colombel J-F, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Russian Journal of Evidence-Based Gastroenterology. 2012;(2):22‑34. (In Russ.)

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Aliment Pharmacol Ther 2011; 33:857-869.

Authors:

Danese S.

Colombel J.-F.

Reinisch W.

Rutgeerts P.J.

Close metadata

References:

  1. Sachar D.B., Andrew H.A., Farmer R.G. et al. Proposed classification of patient subgroups in Crohn's disease. Gastroenterol Intern 1992; 5: 141-154.
  2. Cosnes J., Cattan S., Blain A. et al. Longterm evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250.
  3. Solberg I.C., Vatn M.H., Hoie O. et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-1438.
  4. Munkholm P., Langholz E., Davidsen M., Binder V. Disease activity courses in a regional cohort of Crohn's. Scand J Gastroenterol 1995; 30: 699-706.
  5. Rutgeerts P., Feagan B.G., Lichtenstein G.R. et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-413.
  6. Schnitzler F., Fidder H., Ferrante M. et al. Mucosal healing predicts long-term outcome for maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15: 1295-1301.
  7. Solberg I.C., Lygren I., Jahnsen J. et al. Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut 2008; 57: Suppl. II: A-15.
  8. D'Haens G.R., Panaccione R., Higgins P.D. et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: when to Start, When to Stop, Which Drug to Choose, and How to Predict Response? Am J Gastroenterol 2011; 106: 199-212.
  9. Travis S.P., Stange E.F., Lémann M. et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55: Suppl. 1: i16-i35.
  10. Lichtenstein G.R., Hanauer S.B., Sandborn W.J. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-483.
  11. Lichtenstein G.R., Abreu M.T., Cohen R., Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-987.
  12. Remicade (infliximab) Summary of Product Characteristics (SPC). Leiden, The Netherlands: Centocor BV, 2010.
  13. Humira (adalimumab) Summary of Product Characteristics (SPC). Berkshire, UK: Abbott Labratories Limited, 2010.
  14. Targan S.R., Hanauer S.B., van Deventer S.J.H. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997; 337: 1029-1035.
  15. Lémann M., Mary J.-Y., Duclos B. et al. Infliximab plus azathioprine for steroiddependent Crohn's disease patients: a randomised, placebo-controlled trial. Gastroenterology 2006; 130: 1054-1061.
  16. Colombel J.-F., Sandborn W.J., Reinisch W. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395.
  17. D'Haens G., Baert F., van Assche G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667.
  18. Hyams J., Crandall W., Johanns J. et al. Induction and maintenance infliximab therapy for the treatment of moderateto-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-873.
  19. Feagan B.G., McDonald J., Ponich T. et al. A randomized trial of methotrexate (MTX) in combination with infliximab (IFX) for the treatment of Crohn's disease (CD) [late-breaking abstract]. Gastroenterology 2008; 134: Suppl. 1: 682c.
  20. Hanauer S.B., Sandborn W.J., Rutgeerts P. et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333.
  21. Colombel J.F., Sandborn W.J., Rutgeerts P. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
  22. Feagan B.G., Panaccione R., Sandborn W.J. et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-1499.
  23. Rutgeerts P., D'Haens G., van Assche G. et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease - first results of the EXTEND Trial. Gastroenterology 2009; 136: Suppl. 1: A-116.
  24. Panaccione R., Rutgeerts P., Sandborn W.J. et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 674-688.
  25. Steinhart A.H. Induction therapy in Crohn's disease. In: Williams C.N., Bursey R.F., Gall D.G., Martin F., McLeod R.S., Sutherland L.R., Wallace J.L., eds. Trends in Inflammatory Bowel Disease Therapy 1999. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2000: 128-136.
  26. Yun L., Hanauer S. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2009; 3: 235-248.
  27. Dignass A., Van Assche G., Lindsay J.O. et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010; 4: 28-62.
  28. Chilton F., Collett R.A. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008; 6: 1-14.
  29. Beaugerie L., Seksik P., Nion-Larmurier I. et al. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-656.
  30. Franchimont D., Louis E., Croes F., Belaiche F. Clinical pattern of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol 1998; 10: 821-825.
  31. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-954.
  32. Lapidus A., Bernell O., Hellers G. et al. Clinical course of colorectal Crohn's disease: a 35-year follow up study of 507 patients. Gastroenterology 1998; 114: 1151-1160.
  33. Lichtenstein G.R., Yan S., Bala M. et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-869.
  34. Sandborn W.J., Fazio V.W., Feagan B.G. et al. American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125: 1508-1530.
  35. Sands B.E., Anderson F.H., Bernstein C.N. et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885.
  36. Lichtenstein G.R., Olson A., Travers S. et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006; 101: 1030-1038.
  37. Munkholm P., Langholz E., Davidsen M., Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716-1723.
  38. Eshuis E.J., Bemelman W.A., van Bodegraven A.A. et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). BMC Surg 2008; 8: 15.
  39. Hanauer S.B., Feagan B.G., Lichtenstein G.R. et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
  40. Treton X., Bouhnik Y., Mary J.Y. et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-85.
  41. Van Assche G., Magdelaine-Beuzelin C., D'Haens G. et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868.
  42. Lichtenstein G.R., Diamond R.H., Wagner C.L. et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-226.
  43. Sokol H., Seksik P., Carrat F. et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-1368.
  44. Markowitz J., Grancher K., Kohn N., Lesser M., Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
  45. Data on file. Centocor, Inc.
  46. Gisbert J.P., Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-767.
  47. Schnitzler F., Fidder H., Ferrante M. et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
  48. Sandborn W.J., Rutgeerts P., Enns R. et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838.
  49. Allez M., Vermeire S., Mozziconacci N. et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010; 31: 92-101.
  50. Doménech E., Hinojosa J., Nos P. et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005; 22: 1107-1113.
  51. Louis E., Vernier-Massouille G., Grimaud J. et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 2008; 57: A66.
  52. Louis E., Vernier-Massouille G., Grimaud J. et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009; 136: A-146.
  53. Hyder S.A., Travis S.P.L., Jewell D.P. et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49: 1837-1841.
  54. Tougeron D., Savoye G., Savoye-Collet C. et al. Predicting factors of fistula healing and clinical remission after infliximabbased combined therapy for perianal fistulizing Crohn's disease. Dig Dis Sci 2009; 54: 1746-1752.
  55. Lichtenstein G.R., Feagan B.G., Cohen R.D. et al. Serious infections and mortality in association with therapies or Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-630.
  56. Sutherland L.R., Ramcharan S., Bryant H., Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98: 1123-1128.
  57. Lindberg E., Järnerot G., Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. Gut 1992; 33: 779-782.
  58. Reese G.E., Constantinides V.A., Simillis C. et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2410-2422.
  59. Gearry R.B., Roberts R.L., Burt M.J. et al. Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflamm Bowel Dis 2007; 13: 1220-1227.
  60. Armuzzi A., Amah T., Ling K.L. et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 2003; 52: 1133-1139.
  61. Boirivant M., Leoni M., Tariciotti D., Fais S., Squarcia O., Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988; 10: 401-405.
  62. Allez M., Lemann M., Bonnet J., Cattan P., Jian R., Modigliani R. Term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97: 947-953.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.